Ozmosi | Iseganan Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Iseganan

Alternative Names: iseganan
Clinical Status: Inactive
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action:

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Head and Neck Cancer|Stomatitis|Mucositis|Pneumonia, Ventilator-Associated

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT00022373

CDR0000068810

P3

Unknown status

Head and Neck Cancer|Stomatitis|Mucositis

None

2019-03-21

Treatments

NCT00118781

NCT00118781

P3

Terminated

Pneumonia, Ventilator-Associated

None

2019-03-21

Treatments